{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-26-000076","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.371652+00:00","generated_at":"2026-05-15T06:27:41.295984+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr","bullets":["Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).","GAAP net earnings $5.24B ($2.14 diluted EPS) vs $11.0B ($4.54) in Q1 2025, down 52% due to prior-year other income.","Adjusted net earnings $6.61B ($2.70 diluted EPS) vs $6.71B ($2.77), down 1.4% YoY.","Dividend increased 3.1% to $1.34 per quarter ($5.36 annual), marking 64th consecutive annual increase; payable June 9, 2026 to record May 26.","Innovative Medicine segment sales $15.4B (+11.2%); MedTech $8.6B (+7.7%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-26-000076","json":"https://secwatch.observer/filing/0000200406-26-000076.json","markdown":"https://secwatch.observer/filing/0000200406-26-000076.md","text":"https://secwatch.observer/filing/0000200406-26-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/0000200406-26-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/jnj-20260414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:27:41.295984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29109476ca18a564470a2c5cc21f6e6b2c3c5563","claim":"JOHNSON & JOHNSON reported first quarter ended March 29, 2026 results: revenue $24,062, net income $5,235, EPS $2.14.","evidence_excerpt":"5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide $24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and subsidiaries","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/0000200406-26-000076-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 29, 2026"},{"label":"Revenue","value":"$24,062"},{"label":"Net income","value":"$5,235"},{"label":"EPS","value":"$2.14"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}